tbuckley/cabot-search huggingface dataset:
Psychosocial distress among cancer patients: A single institution experience at the state of Qatar.
Authors: Azza Adel Hassan, Saad Jobran Eziada, Abdelsadiq Bashir, Amna Gameil, Hind Elmalik, Ayman Allam
Journal: Journal of Clinical Oncology (2018)

e22163 Background: The prevalence of psychosocial distress is up to 45% among cancer patients. It is crucial to identify and treat distress in order to improve quality of life, satisfaction and assure adherence to cancer therapy and ultimately increase survival rates. The aim of the study is to not only report on prevalence of distress among cancer patients, but to also analyze the effect of the disease stage using the Distress Thermometer. Methods: We studied distress among 3 groups, each consisting of 100 patients: those initially diagnosed, patients undergoing treatment, and patients who were referred to the palliative team. Different variables such as time of screening, sex, age, nationality, and tumor type were analyzed. Results: There was an overall incidence of 62% (level ≥ 4) and 17% (level > 7) patients having severe distress. Similarly, there was 75% of distress among patients who were referred to palliative care, whereas those who were at their initial phase (56%) and undergoing treatment (54%). In addition, women (69%) had more distress than men (53%). Expatriates had higher levels of distress, compared to Qataris (51% versus 7% p= 0.001). Breast (69%) and lung (70%) cancer patients had the most distress. Physical causes of distress were the most common (80%), followed by emotional causes (69%). Conclusions: There is a substantial presence of distress among patients in Qatar, than reported internationally. Patients referred to palliative care, those with breast and lung cancers had the highest level of distress. Distress screening should be considered as an essential component of assessment of patients diagnosis, repeated at regular intervals especially at the time of disease progression. Screening alone is not enough, the different causes of its presence should be identified and addressed by the appropriate interventions.
Journal of Laryngology and Otology, London
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The cholecystokinin-A receptor mediates inhibition of food intake yet is not essential for the maintenance of body weight
Authors: Alan S. Kopin, Wendy Foulds Mathes, Edward W. McBride, Minh Nguyen, Wisam Al-Haider, Frank Schmitz, Susan Bonner-Weir, Robin Kanarek, Martin Beinborn
Journal: Journal of Clinical Investigation (1999)

ErrataFigure 2 CCK-8 induced inhibition of food intake is mediated through the CCK-A receptor.After an overnight fast, animals were injected with either saline or CCK-8 and provided access to chocolate-flavored Ensure as described in Methods.Cumulative intake (mean ± SEM) over a 15-min period after injection is shown.Significance vs. intake after saline injection (0 µg CCK-8/kg body weight [BW]): *P < 0.05, **P < 0.01.(a) CCK-8 induced, dose-dependent inhibition of food intake is observed in wild-type (WT), but not in CCK-AR -/-mice.Food consumption by 10 wild-type and 10 CCK-AR -/-animals was compared.ANOVA parameters were [F(3,39) = 89.23,P < 0.0001] and [F(3,39 )= 0.16, P = 0.92] for comparisons among wild-type and CCK-AR -/-animals, respectively.(b).CCK-8 induced, dosedependent inhibition of food intake is observed in both wild-type and CCK-BR -/-mice.Food consumption by 9 wild-type and 10 CCK-BR -/-animals was compared.ANOVA parameters were [F(3,35) = 44.40,P < 0.0001] and [F(3,39) = 135.21,P < 0.0001] for comparisons among wildtype and CCK-BR -/-animals, respectively.BW, body weight.
Ascorbic acid and vitamin B12
Authors: H. L. Newmark
Journal: JAMA (1979)

Using extraction procedures in which the extracted vitamin B<sub>12</sub>was protected by cyanide or metabisulfite, several investigators found no change in vitamin B<sub>12</sub>when meals were incubated in the presence of ascorbic acid for 30 minutes at 37 °C. A previous report suggested degradation of vitamin B<sub>12</sub>under these conditions, but this was apparently caused by incomplete protection of the extracted vitamin B<sub>12</sub>in the assay procedure. If incubation at 37 °C for 30 minutes is a laboratory mimic of the gastric environment, one must conclude that high doses of ascorbic acid do not affect the stability of vitamin B<sub>12</sub>in vivo. (<i>JAMA</i>242:2319-2320, 1979)
Liver function in early Lyme disease
Authors: H Horowitz
Journal: Hepatology (1996)

To evaluate the frequency, pattern, and severity of liver function test abnormalities in patients with Lyme disease associated with erythema migrans (EM), 115 individuals with no other identifiable cause for liver function test abnormalities who presented with EM between July 1990 and September 1993 were prospectively evaluated. For individuals with abnormal liver function tests, common causes of hepatitis, including hepatitis A, B, and C, were excluded. A local control group was used for comparison. Forty-six (40%) patients had at least one liver test abnormality, and 31 (27%) had more than 1 abnormality compared with 19 (19%) and 4 (4%) of controls, respectively (P < .01 for each comparison). γ-Glutamyl transpeptidase (28%) and alanine transaminase (ALT) (27%) were the most frequently elevated liver function tests among Lyme disease patients. Anorexia, nausea, or vomiting was reported by 30% of patients, but did not occur more frequently in patients with elevated liver function tests compared with those with normal values. Patients with early disseminated Lyme disease were more likely to have elevated liver function studies (66%) compared with patients with localized disease (34%) (P = .002). After antibiotic treatment, elevated liver function tests improved or resolved in most patients. Liver function test abnormalities are common in patients with EM but were mild, most often not associated with symptoms, and improved or resolved by 3 weeks after the onset of antibiotic therapy in most patients.
THE SPECIFIC GRAVITY OF HUMAN BLOOD.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE DECREASING BIRTH-RATE SCARE.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Eugenic Sterilization in the United States: A Comparative Summary of Statutes and Review of Court Decisions
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Correction of a Statement in the Article under the Title of Nursing Cancer Patients in Their Homes Published in the Journal of March 22, 1928
Authors: George Bigelow
Journal: New England Journal of Medicine (1928)

Dear Sir-I am unable to express my gratitude and thanks to you and your assistants, for the very great assurance, help, and relief, in the unfortunate, undesirable, and trying situation that I have passed through in the last fifteen months.I seem to feel much improved in health
Pembrolizumab (MK-3475) for previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: Phase II KEYNOTE-180 study.
Authors: Manish A. Shah, Jaafar Bennouna, Lin Shen, Peter C. Enzinger, Qiao Li, Ildiko Csiki, Minori Koshiji, Toshihiko Doi
Journal: Journal of Clinical Oncology (2016)

TPS189 Background: PD-L1 is frequently overexpressed in esophageal cancer. Pembrolizumab is a humanized monoclonal antibody that targets the PD-1 receptor and blocks interaction with PD-L1 and PD-L2. In the multicohort, phase Ib KEYNOTE-028 trial, pembrolizumab showed manageable toxicity, a 30.4% ORR, and median duration of response of 40 wk in 23 patients (pts) with PD-L1 + advanced esophageal cancer. The single-arm, multicenter phase II KEYNOTE-180 trial is designed to further evaluate pembrolizumab as a monotherapy in pts with previously treated advanced/metastatic esophageal cancer. Methods: Key eligibility criteria include age ≥ 18 y, advanced/metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type I adenocarcinoma of the esophagogastric junction (EGJ), measurable disease, documented progression during or after 2 prior lines of therapy, ECOG PS 0-1, no active autoimmune disease or brain metastases, and provision of a tumor sample for retrospective biomarker analysis. Pts with metastatic Siewert type I EGJ adenocarcinoma must have known HER2 status and, if HER2 + , must have documented progression on treatment containing trastuzumab. Eligible pts will receive pembrolizumab 200 mg Q3W for 35 cycles (~2 y) or until progression, unacceptable toxicity, or investigator or pt decision. Response will be assessed every 9 wk per RECIST v1.1 and RECIST adapted for immunotherapy response patterns. Treatment may be discontinued for pts who have a CR, and eligible pts may continue treatment beyond initial RECIST-defined progression. AEs will be assessed throughout treatment and for 30 d thereafter (up to 90 d for serious AEs) and graded per NCI CTCAE v4.0. Pts will be followed for survival every 9 wk. The primary efficacy end point is ORR per RECIST v1.1 by central review. Secondary end points include PFS, OS, and duration of response. Exploratory analyses include evaluation of immune-related gene expression profiles and PD-L1 expression status as predictors of pembrolizumab efficacy. Enrollment in KEYNOTE-180 is expected to begin in October 2015 and will continue until approximately 100 pts are enrolled.
“Exhaled nitric oxide and the risk of wheezing in infancy: the Generation R Study.” C. Gabriele, V.W. Jaddoe, E. van Mastrigt, L.R. Arends, A. Hofman, H.A. Moll and J.C. de Jongste.<i>Eur Respir J</i>2012; 39: 567–572.: Table 4
Journal: European Respiratory Journal (2012)
Seventh Symposium of the International Committee on Laboratory Animals
Journal: JNCI Journal of the National Cancer Institute (1979)

Journal Article Seventh Symposium of the International Committee on Laboratory Animals Get access JNCI: Journal of the National Cancer Institute, Volume 62, Issue 4, April 1979, Pages 1117–1118, https://doi.org/10.1093/jnci/62.4.1117-h Published: 01 April 1979
Booknote
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition
Authors: Carolina Pereira, Pol Gimenez-Xavier, Eva Pros, Maria J. Pajares, Massimo Moro, Antonio Gomez, Alejandro Navarro, Enric Condom, Sebastian Moran, Gonzalo Gomez-Lopez, Osvaldo Graña, Miriam Rubio-Camarillo, Alex Martinez-Martí, Jun Yokota, Julian Carretero, Jose M. Galbis, Ernest Nadal, David Pisano, Gabriella Sozzi, Enriqueta Felip, Luis M. Montuenga, Luca Roz, Alberto Villanueva, Montse Sanchez-Cespedes
Journal: Clinical Cancer Research (2016)

Purpose: We aimed to maximize the performance of detecting genetic alterations in lung cancer using high-throughput sequencing for patient-derived xenografts (PDXs). Experimental Design: We undertook an integrated RNA and whole-exome sequencing of 14 PDXs. We focused on the genetic and functional analysis of β2-microglobulin (B2M), a component of the HLA class-I complex. Results: We identified alterations in genes involved in various functions, such as B2M involved in immunosurveillance. We extended the mutational analysis of B2M to about 230 lung cancers. Five percent of the lung cancers carried somatic mutations, most of which impaired the correct formation of the HLA-I complex. We also report that genes such as CALR, PDIA3, and TAP1, which are involved in the maturation of the HLA-I complex, are altered in lung cancer. By gene expression microarrays, we observed that restitution of B2M in lung cancer cells upregulated targets of IFNα/IFNγ. Furthermore, one third of the lung cancers lacked the HLA-I complex, which was associated with lower cytotoxic CD8+ lymphocyte infiltration. The levels of B2M and HLA-I proteins correlated with those of PD-L1. Finally, a deficiency in HLA-I complex and CD8+ infiltration tended to correlate with reduced survival of patients with lung cancer treated with anti-PD-1/anti-PD-L1. Conclusions: Here, we report recurrent inactivation of B2M in lung cancer. These observations, coupled with the mutations found at CALR, PDIA3, and TAP1, and the downregulation of the HLA-I complex, indicate that an abnormal immunosurveillance axis contributes to lung cancer development. Finally, our observations suggest that an impaired HLA-I complex affects the response to anti-PD-1/anti-PD-L1 therapies. Clin Cancer Res; 23(12); 3203–13. ©2016 AACR.
<i>SHANK3,</i>the Synapse, and Autism
Journal: New England Journal of Medicine (2011)

were known to be diploid for chromosomes 12 and 14 were also sequenced as reference libraries.Using our previously described method, 2 we determined whether the maternal sample (PL565) was diploid in each of 22 nonoverlapping 4-Mb regions on chromosomes 12 and 14 through a pairwise comparison with each of the reference libraries.We detected a 4-Mb depletion in DNA copy number on chromosome 12p in PL565 in all seven pairwise comparisons with a normal sample (adjusted P≤0.05 for all comparisons) (Fig. S1 in the Supplementary Appendix, available with the full text of this letter at NEJM .org).Tests for all other 21 regions resulted in nonsignificant adjusted P values for all seven pairwise comparisons (Table S1 in the Supplementary Appendix).
Increased production of nitric oxide by neutrophils and monocytes from cirrhotic patients with ascites and hyperdynamic circulation*1, *2
Authors: G LAFFI
Journal: Hepatology (1995)

An increased release of nitric oxide (NO), a powerful vasodilating agent, has been proposed to play a role in the pathogenesis of vasodilation and hyperdynamic circulation associated with advanced cirrhosis. We evaluated NO synthase (NOS) activity in peripheral leukocytes of 12 cirrhotic patients and 9 healthy subjects together with plasma endotoxin levels and systemic hemodynamic (by a noninvasive echocardiographic method). NOS activity was evaluated by (1) measuring the capacity of isolated polymorphonuclear cells (PMNs) and monocytes to convert [3[H]arginine to [3[H]citrulline; (2) measuring the ability of neutrophils and monocytes to inhibit thrombin-induced platelet aggregation and to increase guanosine 3′-5′-cyclic monophosphate content in coincubated platelets, an expression of NO release from these cells. Both neutrophils and monocytes from cirrhotic patients produced significantly higher amounts of [3h]citrulline than cells obtained from healthy subjects (P < .001 and P < .02 for neutrophils and monocytes, respectively) and were more effective than control cells in inhibiting platelet aggregation (P < .05 and P < .001, respectively for 2 ×106 cells) and in increasing guanosine 3′-5′-cyclic monophosphate content in coincubated platelets (P < .05 and P < .001, respectively). The anti-aggregating activity expressed by leukocytes has a pharmacological profile similar to that described for NO, because it increased after addition of superoxide dismutase, a superoxide anion scavenger, and markedly decreased after inhibition of nitric oxide synthesis with NG-monomethyl-l-arginine (L-NMMA) and NG-nitro-l-arginine-methyl ester (LNAME). Cirrhotic patients had significantly higher plasma endotoxin levels (P < .001) and cardiac index (P < .01) when compared with controls. These data support the contention that the NO synthetic pathway is activated in cirrhotic patients with ascites, hyperdynamic circulation, and endotoxemia.
JNCI Monographs #43, #44, and #45
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article JNCI Monographs #43, #44, and #45 Get access JNCI: Journal of the National Cancer Institute, Volume 58, Issue 6, June 1977, Page 1878, https://doi.org/10.1093/jnci/58.6.1878 Published: 01 June 1977
SYSTEMIC LUPUS ERYTHEMATOSUS AND RENAL TRANSPLANTATION
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal